Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

With the goal of identifying genes with a differential pattern of expression between ovarian serous papillary carcinomas (OSPCs) and normal ovarian (NOVA) epithelium and using this knowledge for the development of novel diagnostic and therapeutic markers for ovarian cancer, we used oligonucleotide microarrays with probe sets complementary to 12,533 genes to analyze the gene expression profiles of 10 primary OSPC cell lines, 2 established OSPC cell lines (UCI‐101, UCI‐107) and 5 primary NOVA epithelial cultures. Unsupervised analysis of gene expression data identified 129 and 170 genes that exhibited >5‐fold upregulation and downregulation, respectively, in primary OSPC compared to NOVA. Genes overexpressed in established OSPC cell lines had little correlation with those overexpressed in primary OSPC, highlighting the divergence of gene expression that occurs as a result of long‐term in vitro growth. Hierarchical clustering of the expression data readily distinguished normal tissue from primary OSPC. Laminin, claudin 3, claudin 4, tumor‐associated calcium signal transducers 1 and 2 (TROP‐1/Ep‐CAM, TROP‐2), ladinin 1, S100A2, SERPIN2 (PAI‐2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase (TADG‐15) and stratifin were among the most highly overexpressed genes in OSPC compared to NOVA. Downregulated genes in OSPC included transforming growth factor‐β receptor III, platelet‐derived growth factor receptor α, SEMACAP3, ras homolog gene family member I (ARHI), thrombospondin 2 and disabled‐2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2). Differential expression of some of these genes, including claudin 3, claudin 4, TROP‐1 and CD24, was validated by quantitative RT‐PCR and flow cytometry on primary OSPC and NOVA. Immunohistochemical staining of formalin‐fixed, paraffin‐embedded tumor specimens from which primary OSPC cultures were derived further confirmed differential expression of CD24 and TROP‐1/Ep‐CAM markers on OSPC vs. NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type‐specific therapies against this disease. © 2004 Wiley‐Liss, Inc.

[1]  T. Ganesan,et al.  Tumour suppressor genes in sporadic epithelial ovarian cancer. , 2002, Reproduction.

[2]  J. F. Harris,et al.  Osteopontin expression in lung cancer. , 1996, Lung cancer.

[3]  M. Carcangiu,et al.  Expression of plasminogen activator inhibitor‐2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF‐1 , 1997, International journal of cancer.

[4]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[5]  J. Packeisen,et al.  Detection of surface antigen 17-1A in breast and colorectal cancer. , 1999, Hybridoma.

[6]  P. Altevogt,et al.  The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. , 2000, Cancer research.

[7]  H. Kleinman,et al.  YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. , 1987, Science.

[8]  B. McClane.  The complex interactions between Clostridium perfringens enterotoxin and epithelial tight junctions. , 2001, Toxicon : official journal of the International Society on Toxinology.

[9]  H. Hsu,et al.  Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. , 1995, Cancer research.

[10]  J. Gogusev,et al.  Expression of the human nephron differentiation molecules in renal cell carcinomas. , 1990, The American journal of pathology.

[11]  H. Kleinman,et al.  Role of laminin in ovarian cancer tumor growth and metastasis via regulation of Mdm2 and Bcl-2 expression. , 2001, International journal of oncology.

[12]  P. Dettmar,et al.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.

[13]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[14]  C. Sotiriou,et al.  Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma , 2003, Molecular carcinogenesis.

[15]  D. Katsaros,et al.  Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Zhan,et al.  Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. , 2003, Blood.

[17]  K. Fujimoto,et al.  Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Altevogt,et al.  CD24 is a marker for human breast carcinoma. , 1999, Cancer letters.

[20]  J. Kemp,et al.  Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. , 1994, American journal of clinical pathology.

[21]  John Clarke,et al.  The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells , 1999, Cancer.

[22]  A. Chambers,et al.  Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter , 2004, Clinical & Experimental Metastasis.

[23]  K. Huebner,et al.  Retroposition in a family of carcinoma-associated antigen genes , 1993, Molecular and cellular biology.

[24]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[25]  A. Jazaeri,et al.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  George M Yousef,et al.  Human tissue kallikreins: a family of new cancer biomarkers. , 2002, Clinical chemistry.

[27]  C. Pilarsky,et al.  CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. , 2002, The American journal of pathology.

[28]  S. Bicciato,et al.  Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. , 2003, Cancer research.

[29]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[30]  K. Shigemasa,et al.  Increased Expression of Protease M in Ovarian Tumors , 1999, Tumor Biology.

[31]  T. O'brien,et al.  Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer , 2002, Expert review of anticancer therapy.

[32]  R. Burgeson,et al.  Comparative Analysis of the Distribution of Laminin Chains in the Basement Membranes in Some Malignant Epithelial Tumors: The α1 Chain of Laminin Shows a Selected Expression Pattern in Human Carcinomas , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  A. Skubitz,et al.  CD44 and β1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins , 2004, Clinical & Experimental Metastasis.

[34]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[35]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David I. Smith,et al.  Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. , 2002, Cancer research.

[37]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[38]  K. Shigemasa,et al.  Ovarian Tumor Cells Express a Transmembrane Serine Protease: A Potential Candidate for Early Diagnosis and Therapeutic Intervention , 2000, Tumor Biology.

[39]  Kornelia Polyak,et al.  Cellular and molecular targets of estrogen in normal human breast tissue. , 2002, Cancer research.

[40]  J. Mascarello,et al.  Characterization and development of UCI 107, a primary human ovarian carcinoma cell line. , 1996, Gynecologic oncology.

[41]  A. Manetta,et al.  Characterization of a human ovarian carcinoma cell line: UCI 101 , 1993, Gynecologic oncology.

[42]  G. Parham,et al.  Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells , 2000, Obstetrics and gynecology.

[43]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[44]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Birchmeier,et al.  Monoclonal antibodies which prevent experimental lung metastases , 1984, FEBS letters.

[46]  Klaus Ley,et al.  CD24 mediates rolling of breast carcinoma cells on P‐selectin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  R. L. Baldwin,et al.  Differential gene expression between normal and tumor-derived ovarian epithelial cells. , 2000, Cancer research.

[48]  D R Flower,et al.  The lipocalin protein family: structure and function. , 1996, The Biochemical journal.

[49]  R. Stahel,et al.  CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. , 1992, Cancer research.

[50]  A. Skubitz,et al.  CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. , 2000, Clinical & experimental metastasis.

[51]  T. Bratt,et al.  Lipocalins and cancer. , 2000, Biochimica et biophysica acta.

[52]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[53]  H. A. Bakker,et al.  Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.

[54]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  O. Cummings,et al.  Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. , 2001, Cancer research.

[56]  J. Dickinson,et al.  Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. , 1995, The Journal of biological chemistry.

[57]  C. V. D. van de Velde,et al.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. , 1994, Cancer research.

[58]  D R Schwartz,et al.  Coordinately up-regulated genes in ovarian cancer. , 2001, Cancer research.

[59]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Y. Nagashima,et al.  Overexpression of Laminin γ2 Chain Monomer in Invading Gastric Carcinoma Cells , 1999 .

[61]  Tatjana Crnogorac-Jurcevic,et al.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. , 2002, The American journal of pathology.

[62]  A. Oates,et al.  The role of osteopontin in tumorigenesis and metastasis. , 1997, Invasion & metastasis.

[63]  L. Distel,et al.  CD24 promotes invasion of glioma cells in vivo. , 1999, Journal of neuropathology and experimental neurology.

[64]  P. Altevogt,et al.  CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. , 1997, Blood.

[65]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[66]  H. Höfler,et al.  Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. , 1995, Cancer research.

[67]  M. Carcangiu,et al.  Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.